Life Sciences INDUSTRIES

We represent industry leaders in biotechnology, pharmaceuticals, medical devices and beyond in confronting and resolving challenges in all aspects of the life sciences industry.

Recognized both globally and nationally as a leading life sciences practice, WilmerHale has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for more than four decades. From biotechnology, pharmaceutical and medical device companies at all stages of growth to venture capitalists and investment banks, we understand the business of our life sciences clients and the changing regulatory, competitive and consumer demands that the industry faces. Our work in supporting life sciences clients has led to the group being named a "Practice Group of the Year" by Law360.

Many of our lawyers have advanced degrees in relevant scientific disciplines and more than 100 of our lawyers devote a significant portion of their practice to aspects critical to life sciences clients. Those aspects include corporate finance, licensing and alliances, mergers and acquisitions, patent prosecution and other intellectual property matters, patent and product liability. We also work with clients on securities, litigation and FDA, competition and other regulatory matters.


Sort By
Der Marderosian, Lia

Lia Der Marderosian

Vice Chair, Corporate Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6982 (t)

Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)


Brian A. Johnson

Co-Chair, Capital Markets

+1 212 937 7206 (t)

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)


We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, licensing agreements and collaborations. We also have protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success.

 Read about some of our recent life sciences transactions.


Our life sciences clients include:

  • Achillion
  • Agios Pharmaceuticals
  • AVEO Pharmaceuticals
  • Biogen IDEC
  • Bristol-Myers Squibb
  • Cephalon
  • Cynosure
  • Curis
  • Dendreon
  • Durata Therapeutics
  • Emergent BioSolutions
  • Epizyme
  • Idenix
  • Idera Pharmaceuticals
  • Infinity Pharmaceuticals
  • The Medicines Company
  • Medtronic
  • Merrimack Pharmaceuticals
  • Novartis
  • Ophthotech Corporation
  • Pacira Pharmaceuticals
  • PerkinElmer
  • PTC Therapeutics
  • Tetraphase Pharmaceuticals
  • Thermo Fisher Scientific

Publications & News


April 4, 2014

Technical and Scientific Experience

Our ability to provide superior legal representation to technology companies is greatly enhanced by the academic and industry experience of our lawyers in a wide variety of technical and scientific fields.    

March 14, 2014

Chambers & Partners Recognizes WilmerHale in its 2014 Global Edition

Thirty-one WilmerHale lawyers have been named among the “World’s Leading Lawyers for Business” in the 2014 edition of Chambers Global. In addition to these individual accolades, 13 of the firm’s practice areas were also recognized.

January 28, 2014

WilmerHale Named Life Sciences Practice Group of the Year by Law360

Law360 has named WilmerHale as a "Life Sciences Practice Group of the Year" for 2013 in its annual competition. Based on the firm's diverse set of knowledge in serving its life sciences clients, the firm is recognized for playing a major role in some of the year's most noteworthy corporate, intellectual property and litigation matters in the life sciences industry.

January 21, 2014

Federal Circuit Finds Patentees Entitled to Additional Patent Term Adjustment

January 3, 2014

Three WilmerHale Practices Named ‘Practice Group of the Year’ by Law360

On January 1, 2014, WilmerHale's Appellate, Intellectual Property and Life Sciences Practices were included in Law360's "Practice Group of the Year" series for 2013.

October 31, 2013

Coming Soon: Paradigm Shift In Genetic Resources Regs

An article by WilmerHale Partner Bruce Manheim, published in the October 28, 2013 edition of Law360.

October 15, 2013

14th Annual Tech and Life Sciences Compensation and Entrepreneurship Study Released

According to an executive compensation study of private businesses released today, non-founder C-suite executives at life sciences and healthcare companies saw their cash compensation increase by three percent year-over-year, while comparable executives at private technology firms experienced an average increase of 1.6 percent.

October 15, 2013

Trevor Cook, the UK’s Leading IP Litigator, Joins WilmerHale

WilmerHale is pleased to announce that Trevor Cook is expected to join the firm as a partner as of January 1, 2014 in its Intellectual Property Litigation Practice Group in New York.

October 1, 2013

Partner Bruce Manheim Publishes Chapter on Food and Drug Litigation Strategies

WilmerHale Partner Bruce Manheim authored a chapter in the newly-released book, Inside the Minds: Food and Drug Litigation Strategies.

October 1, 2013

A Primer: Recent Developments and Strategies in Petitions and Lawsuits Challenging FDA Approval of Generic Drug Products Under the Administrative Procedure Act

A chapter by Bruce Manheim, published in Inside the Minds: Food and Drug Litigation Strategies.


As a result of our skill and experience in the life sciences field, we have received many accolades, including:

  • Chambers USA: America's Leading Lawyers for Business 2007-2013 named WilmerHale among the top law firms for life sciences. In 2013, a source stated that our attorneys are "consistently excellent people" who are "very responsive."
  • Chambers Global 2013 and 2014 recognized WilmerHale as a leader in life sciences with an "outstanding US practice coupled with international reach."
  • Chambers Europe 2013 recognized WilmerHale as a leader in life sciences in Germany.
  • Law360 has named WilmerHale as a "Life Sciences Practice Group of the Year" for 2013 in its annual competition which recognizes five firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year. This is the fourth consecutive year the firm has been named a "Practice Group of the Year" by Law360.
  • Legal 500 US 2013 ranked WilmerHale among the top law firms for life sciences. In the 2013 edition of the guidebook, a source stated that our firm "brings a great deal of experience to any situation" and says that our firm "has access to additional expertise/resources to help solve any problem."
  • LMG Life Sciences ranked the firm in their 2013 edition in the areas of patent prosecution, corporate, and licensing and collaboration. The firm was also named a "Lifecycle Firm," meaning the firm is regarded as one of the best, full-service law firms within the life sciences industry.
  • LMG Life Sciences named WilmerHale the winner of the 2013 "Canadian Impact Deals of the Year" award. The firm was recognized for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP recognized WilmerHale in 2013 as one of the best in the nation and named the firm "National Patent Contentious Firm of the Year" and "Pharmaceutical IP Litigation Firm of the Year"
  • Managing IP named WilmerHale among the top nationally ranked firms in their 2013-14 guide, and received a "Tier 1" ranking in the area of life sciences.
  • PLC Life Sciences Industry Super League 2012 named WilmerHale among the top ten law firms for having "a strong transatlantic life sciences practice."
  • PLC Cross-border Life Sciences Handbook 2011/12, 2009/10, 2008/09, 2007/08 and 2006/07 named WilmerHale a leading law firm in the area of life sciences.
  • The American Lawyer placed WilmerHale on their 2013 "A-List" as one of the nation's leading law firms. This is the tenth year the firm has received this recognition.
  • The American Lawyer recognized WilmerHale as its "IP Litigation Department of the Year" in 2014.
  • The National Law Journal named WilmerHale to the 2012 and 2013 Intellectual Property Hot Lists, which honors firms who demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News – Best Lawyers® ranked the firm in their 2014 edition in the areas of intellectual property and corporate law, and awarded WilmerHale as a first-tier law firm in 27 national and 60 metro-area rankings.